

REMARKS

In the present Amendment, claim 2 has been amended to delete the extra “)” at the last line.

“Use” claim 4 has been amended to be a method claim and claims 5-7 have been added. This amendment and claims 5-7 are supported by the specification, for example, in the test example. Claim 5 is further supported by the specification, for example, by original claim 4.

Claim 4 has also been amended to be in proper multiple form.

Entry of the Amendment is respectfully requested. Upon entry of the Amendment, claims 1-7 will be all the claims pending in the application.

I. Response to Rejections Under 35 U.S.C. §§ 112 and 101

In Paragraph No. 4 of the Office Action, claim 4 was rejected under 35 U.S.C. § 112, second paragraph, as being indefinite, and under 35 U.S.C. § 101 as being an improper process claim, because the claim did not set forth any steps.

In response, Applicants have in the Amendment amended claim 4 to recite specific. Accordingly, the Examiner is respectfully requested to reconsider and withdraw the rejections.

II. Response to Rejection Under 35 U.S.C. § 102

In Paragraph No. 6 of the Office Action, claims 1-3 have been rejected under 35 U.S.C. § 102(a) as allegedly being anticipated by 22nd Symposium on Medicinal Chemistry, 11th Annual meeting of Division of Medicinal Chemistry (hereinafter “SMD”).

In response, Applicants submit herewith a Declaration under 37 C.F.R. § 1.132 executed by Kazutoshi Suzuki, Ming-Rong Zhang, Tetsuya Suhara, Atsuro Nakazato and Makoto Goto, the co-inventors of the present invention. The Declaration establishes that the relevant portions

of the Zhang reference relied upon by the Examiner are the work of the co-inventors. Jun Maeda, Yuichiro Yoshida, Masanao Ogawa, Kenji Furutsuka, Takayo Kida, Junko Noguchi and Takashi Okauchi are co-authors of the Zhang reference, but are not co-inventors of the invention disclosed and claimed in the subject application. Accordingly, the Examiner is respectfully requested to reconsider and withdraw the rejection.

III. Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Fang Liu
Registration No. 51,283

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: November 12, 2004